Provider-initiated HIV/AIDS counselling and testing at healthcare facilities in Thailand: a cluster-randomisation trial. Yot Teerawattananon1, Yuwadee Leelukkanaveera1,2,3, Montarat Thavorncharoensap1,4, Piya Hanvoravongchai5, Lily Ingsrisawang1,6, Sripen Tantivess1, Usa Chaikledkaew1,4, Adun Mohar

A cost-utility and budget impact analysis of allogeneic hematopoietic stem cell transplantation for severe thalassemic patients in Thailand. Pattara Leelahavarong1,2, Usa Chaikledkaew1,2*, Suradej Hongeng3, Vijj Kasemsup4, Yoel Lubell1,5, Yot Teerawattananon1 1Health Intervention and Technolog

Scaling up health policies and services in low- and middle-income settings. Kara Hanson1*, Susan Cleary2, Helen Schneider3, Sripen Tantivess4, Lucy Gilson1,5 1Department of Global Health and Development, London School of Hygiene and Tropical Medicine, UK. 2Health Economics Unit, University of Cap

COVID-19 has been inevitably staying with us for almost a year and a half since the first outbreak. It induces us to seek for more knowledge in order to survive and control this harsh situation, not only from healthcare perspective but also economic and political ones. HTA is a great helping hand fo

Economic Evaluation of Policy Options for Prevention and Control of Cervical Cancer in Thailand Naiyana Praditsitthikorn,1,2 Yot Teerawattananon,1,3 Sripen Tantivess,1,3 Supon Limwattananon,3 Arthorn Riewpaiboon,2 Saibua Chichareon,4 Nantakan Ieumwananonthachai5 and Viroj Tangcharoensathien3

Economic Evaluation of Rehabilitation Services for Inpatients with Stroke in Thailand: A Prospective Cohort Study. Orathai Khiaocharoen, BN, PhD1, , , , Supasit Pannarunothai, MD, PhD2, Wachara Riewpaiboon,MD3, Lily Ingsrisawang, BSc, PhD4, Yot Teerawattananon, MD, PhD5 1 Hea

Advanced health biotechnologies in Thailand: redefining policy directions. Román Pérez Velasco1*, Usa Chaikledkaew2,3, Chaw Yin Myint2 , Roongnapa Khampang2 , Sripen Tantivess2 and Yot Teerawattananon2* Abstract Background: Thailand faces a significant burden in terms of treating and managi

Cost-utility analysis of 10- and 13-valent pneumococcal conjugate vaccines: Protection at what price in the Thai context? Wantanee Kulpenga, b, , , , Pattara Leelahavaronga, , Waranya Rattanavipaponga, , Vorasith Sornsrivichaib, , Henry C. Baggettc, , Aronrag Meeyaia, d, , , Warunee Punpaniche, ,

A cost–utility analysis of alternative drug regimens for newly diagnosed severe lupus nephritis patients in Thailand. Adun Mohara1, Román Pérez Velasco1, Naiyana Praditsitthikorn1,2, Yingyos Avihingsanon3 and Yot Teerawattananon1 1Health Intervention and Technology Assessment Program (HITAP),

Balancing the right to know and the privacy of the patent system: a case study of oncology medicines in Thailand. Inthira Yamabhai; Richard D. Smith Abstract: This study aims to illustrate the processes to determine medicine patent status in developing countries by using oncology medicine in T